Marketing Policy Brief
FDA Review of Pharma Ads Could Reshape D2C Marketing
Requiring more risk and safety information within a TV or radio spot could make pharma ads longer and more complex
The FDA is proposing a rule that could force prescription drug TV and radio ads to include all risk and safety information within the spot itself. The change may reshape pharma D2C campaign strategy, creative development, and media buying across a market that spent nearly $6 billion on national TV drug ads in 2025.
This Is an ANA Member Exclusive
Access to this item is reserved for ANA members only.
Log in
Already have an account? The industry's best insights and resources await:
No Account?
Use your business email address to create your free account; if you're a member through your company, we'll know.
Members can access their benefits as soon as they sign up and log in.
Not a Member?
You can still create a free account to access the latest from our online publication, ANA Magazine, receive content and special event offers through our newsletters, get breaking industry updates, and so much more.
The content you're trying to see is available to:
- ANA Client-Side Marketer Tier Members
- Platinum Tier Members
- Gold Tier Members
- Silver Tier Members
Discover everything the ANA can do to help drive growth for your organization. Connect with our membership team.